Recent Finacing
Recent Raise
Angiex is a Cambridge-based biotechnology company developing Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid tumors, led by its first-in-class candidate AGX101.
Focus Areas
Total Raised
Funding round
See the team members at Angiex.
